{"nctId":"NCT00337571","briefTitle":"Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)","startDateStruct":{"date":"2006-06"},"conditions":["Behavioral Symptoms","Autistic Disorder"],"count":218,"armGroups":[{"label":"A1","type":"EXPERIMENTAL","interventionNames":["Drug: Aripiprazole"]},{"label":"A2","type":"EXPERIMENTAL","interventionNames":["Drug: Aripiprazole"]},{"label":"A3","type":"EXPERIMENTAL","interventionNames":["Drug: Aripiprazole"]},{"label":"B1","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Aripiprazole","otherNames":["Abilify"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Meets current Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) diagnostic criteria for AD and demonstrates serious behavioral problems; diagnosis confirmed by Autism, Diagnostic Interview-Revised (ADI-R).\n* CGI score \\> = 4 AND an ABC Irritability/Agitation subscale score \\> = 18 at screening and baseline (randomization)\n* Mental age of at least 18 months\n* Male or female 6 to 17 years of age inclusive, at the time of randomization\n\nExclusion Criteria:\n\n* Patients considered treatment resistant to neuroleptic medication based on lack of therapeutic response to 2 different neuroleptics after treatment of at least 3 weeks each\n* Patients previously treated and not responding to aripiprazole treatment\n* The patient is currently diagnosed with another disorder on the autism spectrum, including PDD-NOS, Asperger's Disorder, Rett's Disorder, Fragile-X Syndrome or Childhood Disintegrative Disorder\n* Current diagnosis of bipolar disorder, psychosis, schizophrenia, or major depression\n* A seizure in the past year\n* History of severe head trauma or stroke\n* Non-pharmacologic therapy (e.g., psychotherapy, behavior modification) should be stable prior to screening and consistent throughout the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"6 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Change (Week 8 - Baseline) in the Autistic Behavior Checklist (ABC) Irritability Subscale Score","description":"The ABC is a 58-item informant-based assessment of problem behaviors in children/adolescents with mental retardation. Items are rated on a 4-point scale (0=no problem, 3=severe problem), and resolve into 5 domain subscales. A decrease in score indicates improvement.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.4","spread":"1.39"},{"groupId":"OG001","value":"-12.4","spread":"1.36"},{"groupId":"OG002","value":"-13.2","spread":"1.25"},{"groupId":"OG003","value":"-14.4","spread":"1.31"}]}]}]},{"type":"SECONDARY","title":"Mean Clinical Global Impressions Improvement Scale (CGI-I) Score","description":"The CGI scale is a clinician-rated global assessment of a patient's improvement over time. Baseline assessment rated a patient's condition on a 7-point scale (1=no symptoms, 7=very severe symptoms). Subsequent assessed improvement relative to baseline symptoms on a 7-point CGI-I item scale (1=very much improved, 7=very much worse).","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.3","spread":"0.18"},{"groupId":"OG001","value":"2.6","spread":"0.17"},{"groupId":"OG002","value":"2.5","spread":"0.16"},{"groupId":"OG003","value":"2.5","spread":"0.17"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Response at Week 8","description":"Response defined as a â‰¥ 25% reduction from baseline to endpoint in the ABC Irritability Subscale score and a CGI-I score of 1 or 2 at endpoint.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"29","spread":null},{"groupId":"OG002","value":"29","spread":null},{"groupId":"OG003","value":"28","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change (Week 8 - Baseline) in the Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS; Compulsion Scale Only)","description":"CY-BOCS=10-item assessment of obsessive-compulsive symptoms in patients \\<18 years. 5 items pertaining to compulsions rate symptoms (time spent, interference with functioning, distress, resistance, control) on a 5-point scale (0=no symptoms/minimum severity, 4=extreme symptoms/maximum severity). A decreased in value indicates improvement.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.7","spread":"0.50"},{"groupId":"OG001","value":"-2.6","spread":"0.50"},{"groupId":"OG002","value":"-2.4","spread":"0.44"},{"groupId":"OG003","value":"-3.2","spread":"0.47"}]}]}]},{"type":"SECONDARY","title":"Mean Change (Week 8 - Baseline) in the Other ABC Subscale Scores","description":"Mean change (Week 8 - baseline) in the other ABC subscale scores (lethargy/social withdrawal; stereotypic behavior; hyperactivity/ noncompliance; inappropriate speech). A decrease in value indicates improvement.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.7","spread":"1.67"},{"groupId":"OG001","value":"-14.0","spread":"1.64"},{"groupId":"OG002","value":"-13.3","spread":"1.50"},{"groupId":"OG003","value":"-16.3","spread":"1.59"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.8","spread":"0.69"},{"groupId":"OG001","value":"-4.5","spread":"0.68"},{"groupId":"OG002","value":"-4.2","spread":"0.63"},{"groupId":"OG003","value":"-4.5","spread":"0.66"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":"0.46"},{"groupId":"OG001","value":"-2.0","spread":"0.45"},{"groupId":"OG002","value":"-1.8","spread":"0.41"},{"groupId":"OG003","value":"-2.3","spread":"0.43"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.2","spread":"1.16"},{"groupId":"OG001","value":"-5.8","spread":"1.15"},{"groupId":"OG002","value":"-4.9","spread":"1.06"},{"groupId":"OG003","value":"-7.9","spread":"1.11"}]}]}]},{"type":"SECONDARY","title":"Mean Change (Week 8 - Baseline) in CGI-Severity (CGI-S)","description":"A CGI-S assessment (a 7-point scale to evaluate the severity of symptoms) was performed at baseline (1=no symptoms; 7=very severe symptoms). The patient's improvement relative to the symptoms at baseline on were assessed on a 7-point CGI-I (1=very much improved; 7=very much worse). A decrease in value indicates improvement.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"0.16"},{"groupId":"OG001","value":"-0.9","spread":"0.15"},{"groupId":"OG002","value":"-1.0","spread":"0.13"},{"groupId":"OG003","value":"-1.1","spread":"0.15"}]}]}]},{"type":"SECONDARY","title":"Summary of Safety","description":"Deaths, Adverse Events (AEs), Serious AEs (SAEs), Treatment-Emergent AEs and AEs leading to discontinuation","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"8","spread":null},{"groupId":"OG003","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"46","spread":null},{"groupId":"OG002","value":"53","spread":null},{"groupId":"OG003","value":"46","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"37","spread":null},{"groupId":"OG002","value":"50","spread":null},{"groupId":"OG003","value":"39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"13","spread":null},{"groupId":"OG003","value":"12","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Body Weight","description":"Adjusted mean change (Week 8 - baseline) in body weight","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"0.32"},{"groupId":"OG001","value":"1.3","spread":"0.31"},{"groupId":"OG002","value":"1.3","spread":"0.29"},{"groupId":"OG003","value":"1.5","spread":"0.30"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":59},"commonTop":["SEDATION","VOMITING","FATIGUE","INCREASED APPETITE","NASOPHARYNGITIS"]}}}